Cyprotex Share Discussion Threads

[redprince] 01/6/2015 17:04

The 1st such news in a very long time and hopefully the beginning of a new dawn here.


Good news indeed.

[p1nkfish] 01/6/2015 08:40

with US challenges it's still to be better than expectations.
sort out the US and it will be even better still.
good news.

[skinny] 01/6/2015 07:07

Trading update

The financial performance of the Company for the first 5 months of the year is ahead of expectations driven by strong growth in UK revenues and whilst there remain challenges, particularly in the US operations, the Board expects that its full year revenues and profits will exceed current market expectations.

[p1nkfish] 06/5/2015 15:24

yes, private equity too.
Betfair backer.

[bubbleandleek] 06/5/2015 11:06

is this the same richard koch the author?

[p1nkfish] 06/5/2015 10:08

so quiet.
obviously time to look to buy if i didn't already have enough.

[p1nkfish] 06/5/2015 07:30

richard koch as notifiable shareholder, interesting.

[p1nkfish] 28/4/2015 11:14

French cosmetics covered?

[husbod] 16/4/2015 13:11

More jam tomorrow. I'll be a diabetic in need of an assay or two by the time I get any profit out of these.

[buywell2] 15/4/2015 16:41

...... Cyprotex pledge to return to profitability in 2015 ......

15 April 2015

Despite falling into loss Cyprotex remain optimistic, especially on the acquisition of CeeTox which contributed £1.12 million of total revenue.

Macclesfield-based drug testing firm Cyprotex remain positive despite reporting its first operating loss for seven years.

The company showed a £710,000 loss in place of the £610,000 profit of the previous year.

Final results for the year ending December 2014 revealed strong revenue growth, up 18.4 per cent to £11.57m from £9.77m in 2013.

Despite falling into loss Cyprotex remain optimistic, especially on the acquisition of CeeTox which contributed £1.12 million of total revenue.

Another operational highlight was expanding into the BioHub at the former Astra Zeneca Alderley Park site, and transferring a number of staff to accommodate further growth in revenues.

Chairman Ian Johnson said: "2014 was a year of considerable investment for the Company.

"In addition to the CeeTox acquisition which brought access to a range of new assays and customers, particularly in the Cosmetic and Personal Care space, we have invested heavily in several significant new technical projects which considerably widens the Company's potential service offerings to its current and to new customers.

"However, the CeeTox acquisition experienced operational issues before it ran effectively and the new technical projects took longer to validate than we anticipated.

"As a result, whilst revenues grew by 18 per cent we recorded our first operating loss in seven years, which was in line with guidance given at the time of our trading update in November.

"The acquisitions and investments are, however, critical for our future growth and we have every expectation that these will contribute to significant revenue growth and a return to profitability in 2015."

[bigman] 08/4/2015 18:30

still no sign of accounts

[redprince] 05/4/2015 14:36

Buwell2 - it would be much better if you could make a real effort to keep your nose out of shares where you know little to nothing and do not even have an interest other than trying to (and failing) to wind people up in a rather sad and purile attempt to make yourself appear clever.

Indeed given your track record it might be wiser if you stuck to the stocks where you actually know something about the business like this one - they need all the help you can get rather than alienating yourself from potential investors.

Atb.

[buywell2] 04/4/2015 10:45

The following is from a FDA website .... what it says is that approx 1,000 approved drugs now on the market most likely cause DILI drug induced liver injury.






''This is a major reason for drug withdrawal with approximately 1% of hospitalized patients developing drug-induced liver injury that can be caused by ~1000 marketed drugs.''


the FDA says

''Drug-induced liver injury (DILI) is a leading cause of drugs failing during clinical trials as well as being withdrawn from the market. Comparative analysis of drugs based on their DILI potential is an effective approach to discover key mechanisms and risk factors contributing to a decline in the drug development pipeline. However, classifying a drug for DILI potential to support such study is a challenge with no existing commonly adopted practices by the research community. ''



buywell2 says

''Does the use of one rodent and one non rodent animal species in pre clinical toxicity testing as mandated and required by the FDA , for circa the last 50 years help the above ?








What the FDA link does say though is that it seems to be in favour of more biomarker tests

''miRNAs are a newly discovered group of noncoding RNA and meet many of the ideal biomarker criteria of high specificity, sensitivity, and accuracy. The discovery of circulating miRNAs in the urine and blood has created a new approach for the discovery of noninvasive biomarkers of organ injury but there are still open questions regarding the utility of circulating miRNAs in reflecting organ injury and classifying that injury between various agents. A major finding of this study is that common urinary miRNA expression profile is able to distinguish the patterns of the responses to hepatotoxicant versus a nonhepatotoxicant and controls. Although a larger number of chemicals will need to be tested, the findings in these study suggest that urinary miRNA might be a more specific and consistent biomarker of chemical-induced liver injury than existing tests.''

biomarkers

A measurable endpoint that can be used as an indicator of a particular disease or some other physiological state of an organism





Thus Cyprotex is in the latest FDA biomarker frame




Now you might not see the word 'biomarker' in that link above but it is here about 4 times , you have to increase size ( Ctrl with + ) to read it though

see ''Response Parameterization''




It will most probably be either CellCiphr or maybe CellCiphr Premier that the EPA go with to carry out their Toxicity tests on their library of compounds .


Seems the FDA is getting there , ie same page as the EPA , albeit a bit slower

[buywell2] 04/4/2015 09:26

Re latest RNS

Cell-Based Assays in High-Throughput Screening for Drug Discovery


8. CONCLUSIONS AND PERSPECTIVES

Conventional animal tests for studying the biological effects of drugs and phytochemicals including toxins and herbal compounds are expensive and may be
obscured with the actual effects by various other factors.

The animal experiment is also time consuming and may impose a barrier for social acceptance.

A fast,sensitive and reliable method that can be used to quickly and reliably screen potential biological effects of the vast amount and variety of drug candidates and phytochemicals is thus needed in the development of
new health-promoting compounds and cancer-fighting drugs.

Conventional 2D static cell culture systems widely used in current drug discovery campaign have many inherent limitations for proliferation and
cytotoxicity studies.

The newly developed fluorescent cell-based 3D culture systems are fast, sensitive, and physiologically relevant, and can be used more effectively to bridge the gap between biochemical assays and animal tests. It can save time and cost in the drug screening process.

Furthermore, microfluidic microbioreactor array system, incorporating recent
advances in tissue engineering, microfabrication and microfluidics, can be used to culture stem cells and carcinoma cells in 3D fibrous or microfabricated
scaffolds.

Such microfluidic systems operated with continuous perfusion can be used for long-term study of drugs in an in vivo like 3D environment and flow fields. The use of fluorescent cells in the assay also allows for real-time, non-invasive monitoring of cellular responses to drugs and dynamically changing environments.

A microfluidic system can also provideon-chip serial dilutions to generate various concentrations and combinations of multiple drugs to be tested simultaneously on a single chip. In addition, it is also possible to culture multiple cell types in different but interconnected chambers or channels to evaluate cell-cell and cell-environment interactions on a microfluidic chip, providing the biosystem-level drug responses that can only obtained in animal tests so far.

Microfluidic 3D cell-based HTS assays thus can enable the development of in vitro models for studying specific diseases. Such in vitro models may replace animal models and be used more effectively in the exploration of new drugs including phytochemicals for their therapeutic and health benefits. This could
revolutionize the drug discovery process in the near future.

[p1nkfish] 02/4/2015 09:18

no buy-out this side of end of 2017.

[bigman] 02/4/2015 08:41

Thanks Buywell for your view, "that the only way this share will make any gain is by being the company being bought out and not before"
That really is quite an view from someone who I sort of look at as almost an expert on the company as you post so much good information on the story and science of the business.
in a way we agree, me coming from valuing the business from the financial returns of the company and you, I guess, from science and that it would more valuable to someone other than its present shareholders.

The conclusion is there is no point holding this share or investing in it until they have turned the corner, both in financial terms and in growing the business.

I will still keep watching for signs of "green shoots" and the results.

[buywell2] 02/4/2015 07:59

The money will be made when Cyprotex gets bought out ..... not before


The meat on the EPA contracts has not yet been tasted


When the EPA gets tasting then a predator will bite

[p1nkfish] 01/4/2015 20:39

the low float will help and baxter no doubt focussed on the 120p target

[p1nkfish] 01/4/2015 20:38

well it is panning out in a way I am not concerned by.
own quite a few plus loan notes and above water.
it is a 5 yr+ hold and I do expect some good news to land.
the transformation is virtually complete and they are servicing leading pharma names at high throughput.

let's get lucky.

they have substantially diversified offering, market segments and geographies serviced. spread the base and will exhibit greater billing stability and visibility.

now they have a real business. traction is starting.

[bigman] 01/4/2015 19:03

Thanks, Spent a wee bit time looking at things, prior to Christmass they did update part of which is :-
(CRO), today provides the following trading update.

In the Company's interim results announcement of 28 August 2014, Cyprotex announced revenues including acquisitions were up 19% to GBP5.41 million for the first half of the year, with a reported operating loss of GBP584,000 for the same period. At that time we had commented on delays in development programs impacting the Company's performance this year.

Since then the Company has experienced further unforeseen delays with its development work which, coupled with lower than anticipated demand for acquired services, will have an impact on revenues and as a consequence, profitability. Following this, the Company now expects revenues for the year ended 31 December 2014 to be around GBP11.7 million with EBITDA just above break-even.

Commenting, Dr. Anthony Baxter said:

"Whilst we expect revenues to increase in 2014 by around 20% in excess of 2013's revenues, the growth has not been as strong as anticipated given the significant investments we have made this year. This is because we have experienced unforeseen delays in validating these complex new offerings. Most of these new developments have now been validated and the new assays and services have now been launched and we expect them to contribute positively to growth in 2015. Revenues from the newly acquired assets from the CeeTox acquisition have also been softer than expected".

My comments are:-
EBITDA is almost always relates to cash generated by the business, so they expect no cash generation from the business if that is break even.

They have spent on new labs etc ( which should be good for future) and at half year had consumed a couple of £m so I would imagine cash should be about £4m down on last year, by my reckoning about £3m left, but that is very much rule of thumb.

More worrying is last year EBITDA was £1.59m and ended up with PBT of just 200K so using same the losses will be somewhere between £1.1 and £1.5m depending on how much they have been able to capitalise on new labs and people.

of course this is very much a broad brush and making a few assumptions that may well be totally wrong so please take this as just an opinion and do your own homework and assumptions.

But I choose not to invest at this time until I see some numbers, and if they are as I suspect then I would expect the price to come under pressure and that may well be an opportunity to invest for the longer term as their investment must pay off at sometime.

[p1nkfish] 01/4/2015 17:54

Can give you know firm idea except to say that the eco-system of drug deliver/test/release needs CRX and in the past the free cash flow has been very respectable. Substantial spend on equipment and personnel is about the pay off in my opinion.

The eco-system isn't just drug discovery but also approval. For that reason I hold CRX and INS (speeding up application to the FDA once ADME tested to satisfaction).

The shovels companies in Pharma should be less risky than the discovery side.

Good luck whatever you decide.

[bigman] 01/4/2015 14:26

Good to see expansion in US, I don't hold these at the moment, having sold but I still sort of like the business, (especially as I made some money)and at these prices thinking about going back in, however I am concerned about the financial performance as posted a couple of times as to what is expected/brokers forecasts etc. but no one has responded so has no one any idea of what they are likely to deliver ? Also from past years the numbers would have been published by now, Unfortunately that tends to because of bad news but hope not. Again anyone got any vision or view on when numbers are coming out ? I know buywell loves this share but as an clever investor told me " never let the story get in the way of the facts" there are plenty stories but it is financial performance that counts and the share price is low which would indicates also not expecting a stunning performance. But hey this could be the bargain and opportunity of the year, so please anyone got a clue as I really would like a reason to buy. I

[buywell2] 01/4/2015 07:17

Note re my tendering comments for larger contracts in yesterdays posts


"The medium and large pharmaceutical companies who require high capacity and high quality screening with short turnaround times are realising the benefit of working with Cyprotex and as such the number of strategic deals are increasing and are a key factor in the growth of our business."








Cyprotex opens new US lab
31st March 2015


MACCLESFIELD-based Cyprotex, which provides outsourced services to pharmaceutical companies, has expanded in the US.

The company, a specialist in ADME (absorption, distribution, metabolism, and excretion) testing has launched a new high throughput screening laboratory at its facility in Watertown near Boston.

The new lab replicates the highly successful ADME screening lab in Cheshire which has been developed in-house over the past 16 years.

Dr Anthony Baxter, Cyprotex's chief executive said: "Expansion of our high throughput screening facility to the US has always been a much desired part of our growth strategy plans. Our unique software platform combined with state of the art automation and bioanalytical capabilities make us one of the only contract research facilities to be able to screen such large numbers of compounds in such a wide range of assays with relative ease.

"The medium and large pharmaceutical companies who require high capacity and high quality screening with short turnaround times are realising the benefit of working with Cyprotex and as such the number of strategic deals are increasing and are a key factor in the growth of our business."